United States-based GW Pharmaceuticals in collaboration with its United States subsidiary Greenwich Biosciences has introduced EPIDIOLEX (cannabidiol) oral solution CV in the United States, it was reported on Friday.

The product is intended for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age or older. It was approved by the US Food and Drug Administration (FDA) and is the first prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol, a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs.

The firm has launched a comprehensive patient support program called EPIDIOLEX Engage, which is designed to help patients who have been prescribed EPIDIOLEX gain access to therapy. The program provides patient/caregiver-focused education and resources to help reduce out-of-pocket costs or provide product at no cost for eligible patients.